The approval provides adults who have received at least one prior line of therapy with a new iberdomide-based combination, supported by higher minimal residual disease-negative complete response rates than the comparator regimen in EXCALIBER-RRMM.

The differing reimbursement positions highlight how health technology assessment decisions can diverge across UK nations, affecting the timing of patient access to new medicines.

The amended agreement strengthens Exor's long-term commitment to Philips while allowing the healthcare technology investor to increase its maximum shareholding from 20% to 22%.

The collaboration combines HanchorBio's immuno-oncology platform with Taiwan's national precision oncology programme to support biomarker-driven clinical development and translational research.

The agreement gives Sentynl an exclusive pathway to commercialise the Phase III-ready rare lung disease therapy in the US while providing global manufacturing rights and funding support for late-stage development.

The acquisition would add Nordic Pharma’s €190 million-revenue business and Nordimet rheumatoid arthritis franchise while expanding Alfasigma’s direct commercial presence to 18 European countries and adding platforms in Canada and Japan.

The acquisition would add Caelo’s €40 million-revenue API and excipients business and establish the German company as the anchor of Medios’ planned European network for pharmaceutical compounding ingredients.

The acquisition adds SimoTech’s automation engineering and digital manufacturing expertise to Project Farma’s existing life sciences manufacturing services, creating a broader offering spanning facility strategy through GMP operations.

The collaboration pairs BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors while giving BeOne regional rights to the Revolution Medicines assets across selected Asian markets.

The restructuring concentrates aTyr’s resources on a new late-stage study in patients with restrictive lung disease after its first Phase III trial missed its primary endpoint.

The new tool is intended to help health technology developers determine whether a medicinal product falls within the EU’s Joint Clinical Assessment requirements before entering the formal HTA process.

The collaboration will connect ChemoMetec’s XcytoMatic 30 cell counter with Roche’s Cedex Bio Analyzer and establish a joint go-to-market strategy for the combined bioprocess monitoring solution.

The EU Health Technology Assessment Regulation now requires eligible oncology medicines and advanced therapies to undergo a single European clinical assessment, increasing the importance of early evidence planning alongside EMA regulatory development.

The acquisition would add a clinical-stage KCNT1 inhibitor for a rare genetic epilepsy with no FDA-approved treatments, while Actio’s remaining programmes will be transferred into a separate privately held company.

The completed transaction combines Kashiv’s biologics R&D and manufacturing capabilities with Amneal’s commercial infrastructure, giving the company end-to-end control across biosimilar development, production and commercialisation.

The next-generation sequencing companion diagnostic identifies BRAF V600E and V600K variants, helping clinicians determine which melanoma patients may be eligible for FDA-approved BRAF or BRAF/MEK targeted therapies.

The proposed acquisition gives Wise Equity control of a specialist oral solid-dose manufacturer with established capabilities in effervescent, soluble, orally disintegrating and sublingual formulations.

The long-term manufacturing agreement covers 55 oncology and non-oncology products across three Gland Pharma sites, with commercial revenue expected to begin in 2029.

The partnership gives Sobi potential global commercial and development rights to the first-in-class anti-KIR3DL2 antibody while funding Innate’s Phase III programme in cutaneous T-cell lymphoma.

The transaction would give Sobi full ownership of a specialist commercialisation platform spanning seven Latin American markets, building on its $105 million investment in Pint Pharma in 2025.